Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | DRD3 | P35462 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531838 | 0.88 | MMP12 (0.61) | MMP12ALDH1A1HSD17B10TDP1KMT2A | |
| SCHEMBL27443097 | 0.85 | CYP11B1 (0.49) | CYP11B1CYP11B2MMP12ALDH1A1KMT2A | |
| SCHEMBL13932054 | 0.79 | NR3C2 (0.59) | MMP12ALDH1A1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL4267779 | 0.79 | NR3C2 (0.59) | MMP12ALDH1A1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL24508992 | 0.78 | KIF11 (0.54) | CYP11B1CYP11B2MMP12ALDH1A1KMT2A | |
| SCHEMBL276741 | 0.77 | MMP12 (0.51) | CYP11B1CYP11B2MMP12ALDH1A1KMT2A | |
| SCHEMBL3594625 | 0.77 | MMP12 (0.51) | CYP11B1CYP11B2MMP12ALDH1A1KMT2A | |
| SCHEMBL30336661 | 0.77 | MMP12 (0.51) | CYP11B1CYP11B2MMP12ALDH1A1KMT2A | |
| SCHEMBL30799148 | 0.77 | MMP12 (0.51) | CYP11B1CYP11B2MMP12ALDH1A1KMT2A | |
| SCHEMBL1861248 | 0.77 | NR3C2 (0.57) | CYP11B1CYP11B2MMP12PARP1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | MASARYKOVA UNIVERZITA (CZ) | 2023-02-21 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | MASARYKOVA UNIVERZITA (CZ) | 2022-01-06 | — | — | US | disclosed |
| EP-3556755-B1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2021-11-17 | — | — | EP | disclosed |
| EP-3556755-B1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | UNIV MASARYKOVA (CZ) | 2021-11-17 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100203039-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| US-7700624-B2 | 3-aminocyclopentanecrboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1971576-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070149532-A1 | 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
| WO-2007072201-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2005051934-A1 | ANTITHROMBOTIC COMPOUNDS WITH DUAL FUNCTION | UNIVERSITY OF LJUBLJANA (SI) | 2005-06-09 | — | — | WO | disclosed |
| EP-0906294-B1 | BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6177422-B1 | ANTIPSYCHOTIC AGENT WITH REDUCED SIDE EFFECTS | WARNER-LAMBERT COMPANY | 2001-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584742-B2 | Substituted aminothiazoles as inhibitors of nucleases | RNASEH1, DNASE1, FEN1 | CYP11B1 4531/4885CYP11B2 4783/4885MMP12 2647/4885 |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | CYP11B1 2226/4885CYP11B2 2685/4885MMP12 1121/4885 |
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | CYP11B1 1773/4885CYP11B2 1832/4885MMP12 23/4885 |
| US-20100203039-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | CYP11B1 858/4885CYP11B2 901/4885MMP12 302/4885 |
| US-20070149532-A1 | 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors | CCR5, CCR2, ACKR3 | CYP11B1 829/4885CYP11B2 896/4885MMP12 280/4885 |
| US-20220002282-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES | RNASEH1, DNASE1, FEN1 | CYP11B1 4531/4885CYP11B2 4783/4885MMP12 2647/4885 |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | TOP2A, TOP1, TOP2B | CYP11B1 1880/4885CYP11B2 1753/4885MMP12 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.